PhD position in Radiopharmaceutical Sciences

at  Erasmus MC

Rotterdam, Zuid-Holland, Netherlands -

Start DateExpiry DateSalaryPosted OnExperienceSkillsTelecommuteSponsor Visa
Immediate14 Oct, 2024ANG 3 Monthly04 Sep, 2024N/ACell Culture,Radioactivity,Organic Chemistry,EnglishNoNo
Add to Wishlist Apply All Jobs
Required Visa Status:
CitizenGC
US CitizenStudent Visa
H1BCPT
OPTH4 Spouse of H1B
GC Green Card
Employment Type:
Full TimePart Time
PermanentIndependent - 1099
Contract – W2C2H Independent
C2H W2Contract – Corp 2 Corp
Contract to Hire – Corp 2 Corp

Description:

PHD POSITION IN RADIOPHARMACEUTICAL SCIENCES

Molecular Oncology Twins Advancing Treatment and Innovative Cancer Evaluation (MOTIVATE) Molecular Oncology Twins Advancing Treatment and Innovative Cancer Evaluation (MOTIVATE).
Closing date 14-10-2024

JOB DESCRIPTION

radionuclide therapy is that radioactivity doses are delivered in the tumor very accurately. During this treatment, a radiopharmaceutical is administered to the cancer patient. This radiopharmaceutical is combining a radionuclide and a tumor-targeting vector, that selectively binds to a target protein aberrantly upregulated at the surface of the cancer cells. Emissions of beta and/or alpha particles by the radionuclide cause lethal damage to tumor cells. Prior to the treatment, a diagnostic scan is made to assess the localization of the tumor lesions, as well as proper staging and stratification of the patients that can undergo radionuclide therapy. Currently, the diagnostic imaging drug is chemically different from the therapeutic, which can lead to inadequate treatment. Differences between these diagnostic and therapeutic drugs are eliminated by developing theranostic twins. Molecular twins are chemically identical, and therefore they have identical in vivo behavior and can serve for both imaging and therapy. In fact, the molecular twins contain the diagnostic and the therapeutic nuclide, and depending on the application one nuclide is radioactive, whereas the other one is still present but under its non-radioactive form. This innovative approach is based on easily available fluorine-18 for PET-diagnostics combined with b- or a-emitters for therapy. With these twins the right cancer patients are selected for treatment with optimal therapy. In this project funded by NWO-TTW, UMCG and Erasmus MC will develop theranostic twins for treating cancer. The best twin will be prepared for a first-in-man clinical trial.

QUALIFICATIONS AND SKILLS

Applications are invited from enthusiastic and talented young researchers with an active interest in tracer development and translational radiopharmaceutical research. Qualifications and skills:

  • You have a Master’s degree in organic chemistry, (radio)pharmaceutical chemistry or similar.
  • You have already experience in organic chemistry or medicine chemistry.
  • You are at ease operating analytical and preparative HPLC systems.
  • You have excellent command of English, both spoken and written.
  • You have a positive, interactive and agile mindset, and enjoy continuously expanding your experimental and therotical competences.

These criteria are considered advantages, but not requirements:

  • Previous experience in handling radioactivity and performing radiolabeling procedures.
  • Practical experience with cell culture and in vitro assays.
  • Theoretical knowledge of pharmacology and tumor biology.

Before you apply please check our conditions for employment.

Responsibilities:

Please refer the Job description for details


REQUIREMENT SUMMARY

Min:N/AMax:5.0 year(s)

Hospital/Health Care

Pharma / Biotech / Healthcare / Medical / R&D

Health Care

Graduate

Chemistry

Proficient

1

Rotterdam, Netherlands